for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aptevo Therapeutics Inc

APVO.OQ

Latest Trade

7.15USD

Change

0.15(+2.14%)

Volume

4,776

Today's Range

7.00

 - 

7.30

52 Week Range

2.95

 - 

11.69

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.00
Open
7.00
Volume
4,776
3M AVG Volume
1.20
Today's High
7.30
Today's Low
7.00
52 Week High
11.69
52 Week Low
2.95
Shares Out (MIL)
3.23
Market Cap (MIL)
22.63
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Aptevo Therapeutics Dismisses Ernst & Young As Accounting Firm

Orin Hirschman Reports 7.04% Passive Stake In Aptevo Therapeutics

Aptevo Therapeutics Sells Ixinity Hemophilia B Therapy For Estimated Proceeds In Excess Of $100 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aptevo Therapeutics Inc

Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company's technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company's investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company's marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)) and VARIZIG (Varicella Zoster Immune Globulin (Human)).

Industry

Biotechnology & Drugs

Contact Info

2401 4th Ave Ste 1050

SEATTLE, WA

98121-3460

United States

+1.206.8380500

http://aptevotherapeutics.com/

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

4.620

2018

-33.460

2019

-13.860

2020(E)

-7.365
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.22
Price To Book (MRQ)
2.62
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-118.46
Return on Equity (TTM)
-85.43

Latest News

Latest News

BRIEF-Orin Hirschman Reports 7.04% Passive Stake In Aptevo Therapeutics

* ORIN HIRSCHMAN REPORTS 7.04% PASSIVE STAKE IN APTEVO THERAPEUTICS INC AS OF MARCH 2, 2020 - SEC FILING Source text : (http://bit.ly/2TFimcF) Further company coverage:

BRIEF-Aptevo Therapeutics Sells Ixinity Hemophilia B Therapy For Estimated Proceeds In Excess Of $100 Million

* APTEVO THERAPEUTICS SELLS IXINITY HEMOPHILIA B THERAPY FOR ESTIMATED PROCEEDS IN EXCESS OF $100 MILLION

BRIEF-Aptevo Therapeutics Begins Patient Dosing In Phase 2 Clinical Trial Of Otlertuzumab In Peripheral T-Cell Lymphoma

* APTEVO THERAPEUTICS BEGINS PATIENT DOSING IN PHASE 2 CLINICAL TRIAL OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA Source text for Eikon: Further company coverage:

BRIEF-Aptevo Therapeutics Announces Plans To Conduct Phase 2 Study Of Otlertuzumab In Peripheral T-Cell Lymphoma

* APTEVO THERAPEUTICS ANNOUNCES PLANS TO CONDUCT PHASE 2 STUDY OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA

BRIEF-Aptevo Therapeutics files mixed shelf of up to $150 mln

* Aptevo Therapeutics Inc files for mixed shelf of up to $150 million - SEC filing Source text for Eikon: (http://bit.ly/2hvzJMI) Further company coverage:

BRIEF-Aptevo Therapeutics reports third quarter 2017 financial results

* Aptevo Therapeutics reports third quarter 2017 financial results

BRIEF-Aptevo Therapeutics and Alligator Bioscience announced further details of collaboration on ALG.APV-527​

* Aptevo Therapeutics Inc - co, Alligator Bioscience announced further details of companies' collaboration on ALG.APV-527 Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up